Intravitreal therapy for the management of diabetic retinopathy: A concise review

Figure 1 Ranibizumab remains the first-line agent and the standard of care in the management of diabetic macular edema. A: Fundus photograph of the right eye of a patient with moderate non-proliferative diabetic retinopathy shows retinal thickening and hard exudates (arrow) suggestive of clinically significant macular edema (CSME); B: Corresponding swept source optical coherence tomography scan shows intraretinal (arrow-head) and subretinal fluid (asterisk) along with hard exudates (arrow); C and D: Treatment with Intravitreal Ranibizumab (Accentrix^®) resulted in resolution of CSME and improvement in visual acuity from 6/18 to 6/9.